Proteomic differential display identifies upregulated vinculin as a possible biomarker of pancreatic cancer

  • Authors:
    • Yufeng Wang
    • Yasuhiro Kuramitsu
    • Tomio Ueno
    • Nobuaki Suzuki
    • Shigefumi Yoshino
    • Norio Iizuka
    • Xiulian Zhang
    • Junko Akada
    • Masaaki Oka
    • Kazuyuki Nakamura
  • View Affiliations

  • Published online on: August 30, 2012     https://doi.org/10.3892/or.2012.2004
  • Pages: 1845-1850
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pancreatic cancer (PC) is characterized by rapid tumor spread, and very few patients with PC survive for more than 5 years. It is imperative to discover additional diagnostic biomarkers or specific therapeutic targets in order to improve the treatment of patients with PC. In search for useful biomarkers, we analyzed ten pairs of non-cancerous and cancer tissues from patients with PC by two-dimensional gel electrophoresis (2-DE). Nineteen protein spots showed differential expression on 2-DE gels between the cancer and non-cancerous tissues. Six upregulated protein spots were identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as calreticulin, glutathione synthetase, stathmin, vinculin, α-enolase and glyceraldehyde-3-phosphate dehydrogenase. Western blotting demonstrated that vinculin was predominantly expressed in the pancreatic cancer tissues compared with to non-cancerous tissues. Our findings indicate that vinculin may be a clinically useful biomarker of PC.

References

1 

Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar

2 

Kuramitsu Y, Miyamoto H, Tanaka T, Zhang X, Fujimoto M, Ueda K, Tanaka T, Hamano K and Nakamura K: Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines. Proteomics. 9:5078–5089. 2009. View Article : Google Scholar

3 

Luk JM, Lam CT, Siu AF, Lam BY, Ng IO, Hu MY, Che CM and Fan ST: Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics. 6:1049–1057. 2006. View Article : Google Scholar

4 

Roth U, Razawi H, Hommer J, Engelmann K, Schwientek T, Müller S, Baldus SE, Patsos G, Corfield AP, Paraskeva C and Hanisch FG: Differential expression proteomics of human colorectal cancer based on a syngeneic cellular model for the progression of adenoma to carcinoma. Proteomics. 10:194–202. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Kuramitsu Y, Harada T, Takashima M, Yokoyama Y, Hidaka I, Iizuka N, Toda T, Fujimoto M, Zhang X, Sakaida I, et al: Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus. Electrophoresis. 27:1651–1658. 2006. View Article : Google Scholar

6 

Tanaka T, Kuramitsu Y, Fujimoto M, Naito S, Oka M and Nakamura K: Downregulation of two isoforms of ubiquitin carboxyl-terminal hydrolase isozyme L1 correlates with high metastatic potentials of human SN12C renal cell carcinoma cell clones. Electrophoresis. 29:2651–2659. 2008. View Article : Google Scholar : PubMed/NCBI

7 

Kuramitsu Y, Hayashi E, Okada F, Tanaka T, Zhang X, Ueyama Y and Nakamura K: Proteomic analysis for nuclear proteins related to tumour malignant progression: a comparative proteomic study between malignant progressive cells and regressive cells. Anticancer Res. 30:2093–2099. 2010.

8 

Kuramitsu Y, Baron B, Yoshino S, Zhang X, Tanaka T, Yashiro M, Hirakawa K, Oka M and Nakamura K: Proteomic differential display analysis shows up-regulation of 14–3–3 protein sigma in human scirrhous-type gastric carcinoma cells. Anticancer Res. 30:4459–4465. 2010.

9 

Kuramitsu Y, Taba K, Ryozawa S, Yoshida K, Zhang X, Tanaka T, Maehara S, Maehara Y, Sakaida I and Nakamura K: Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res. 30:3367–3372. 2010.

10 

Kuramitsu Y, Hayashi E, Okada F, Zhang X, Tanaka T, Ueyama Y and Nakamura K: Staining with highly sensitive Coomassie brilliant blue SeePico™ stain after Flamingo™ fluorescent gel stain is useful for cancer proteomic analysis by means of two-dimensional gel electrophoresis. Anticancer Res. 30:4001–4005. 2010.PubMed/NCBI

11 

Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Mikuria K, Fujimoto M, Maehara S, Maehara Y, Okita K, Nakamura K and Sakaida I: Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol. 31:1345–1350. 2007.PubMed/NCBI

12 

Volberg T, Geiger B, Kam Z, Pankov R, Simcha I, Sabanay H, Coll JL, Adamson E and Ben-Ze’ev A: Focal adhesion formation by F9 embryonal carcinoma cells after vinculin gene disruption. J Cell Sci. 108:2253–2260. 1995.PubMed/NCBI

13 

Xu W, Baribault H and Adamson ED: Vinculin knockout results in heart and brain defects during embryonic development. Development. 125:327–337. 1998.PubMed/NCBI

14 

Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M, Hamano K, Okita K, Sakaida I and Nakamura K: Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol. 30:849–855. 2007.

15 

Bakolitsa C, Cohen DM, Bankston LA, Bobkov AA, Cadwell GW, Jennings L, Critchley DR, Craig SW and Liddington RC: Structural basis for vinculin activation at sites of cell adhesion. Nature. 430:583–586. 2004. View Article : Google Scholar : PubMed/NCBI

16 

Rüdiger M: Vinculin and alpha-catenin: shared and unique functions in adherens junctions. Bioessays. 20:733–740. 1998.PubMed/NCBI

17 

Rodríguez Fernández JL, Geiger B, Salomon D, Sabanay I, Zöller M and Ben-Ze’ev A: Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA. J Cell Biol. 119:427–438. 1992.PubMed/NCBI

18 

Subauste MC, Pertz O, Adamson ED, Turner CE, Junger S and Hahn KM: Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility. J Cell Biol. 165:371–381. 2004. View Article : Google Scholar : PubMed/NCBI

19 

Frisch SM and Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 124:619–626. 1994. View Article : Google Scholar : PubMed/NCBI

20 

Ruiz C, Holz DR, Oeggerli M, Schneider S, Gonzales IM, Kiefer JM, Zellweger T, Bachmann A, Koivisto PA, Helin HJ, et al: Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer. J Pathol. 223:543–552. 2011. View Article : Google Scholar : PubMed/NCBI

21 

Thorsen K, Sørensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, Kruhøffer M, Laurberg S, Borre M, Wang K, et al: Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics. 7:1214–1224. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Ziegler WH, Liddington RC and Critchley DR: The structure and regulation of vinculin. Trends Cell Biol. 16:453–460. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November 2012
Volume 28 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, Y., Kuramitsu, Y., Ueno, T., Suzuki, N., Yoshino, S., Iizuka, N. ... Nakamura, K. (2012). Proteomic differential display identifies upregulated vinculin as a possible biomarker of pancreatic cancer. Oncology Reports, 28, 1845-1850. https://doi.org/10.3892/or.2012.2004
MLA
Wang, Y., Kuramitsu, Y., Ueno, T., Suzuki, N., Yoshino, S., Iizuka, N., Zhang, X., Akada, J., Oka, M., Nakamura, K."Proteomic differential display identifies upregulated vinculin as a possible biomarker of pancreatic cancer". Oncology Reports 28.5 (2012): 1845-1850.
Chicago
Wang, Y., Kuramitsu, Y., Ueno, T., Suzuki, N., Yoshino, S., Iizuka, N., Zhang, X., Akada, J., Oka, M., Nakamura, K."Proteomic differential display identifies upregulated vinculin as a possible biomarker of pancreatic cancer". Oncology Reports 28, no. 5 (2012): 1845-1850. https://doi.org/10.3892/or.2012.2004